

## Literatura ACTA MEDICINAE 9/2019 Revmatologie

- 2 **Strukturu modifikující léčba u osteoartrózy. Mýtus, nebo realita?**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Osteoporóza u mužů**  
prof. MUDr. Jan Štěpán, DrSc. Revmatologický ústav a 1. LF UK, Praha
- 2 **Inhibitory tumor nekrotizujícího faktoru alfa nebo inhibitory interleukinu 17 v terapii pacientů s axiální spondyloartritidou?**  
MUDr. Monika Gregová, Ph.D. Revmatologický ústav, Klinika revmatologie 1. LF UK, Praha
- 3 **Léčba polymorbidního pacienta s revmatoidní artritidou v kazuistikách a možnosti uplatnění nového inhibitoru IL-6**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 4 **Pokroky v léčbě plicní arteriální hypertenze u systémových onemocnění pojiva**  
doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 4 **Sexuální dysfunkce u pacientů s chronickým revmatickým onemocněním – problém, o kterém se příliš nemluví**  
Mgr. Barbora Heřmánková | Mgr. Maja Špiritović Fakulta tělesné výchovy a sportu, Katedra fyzioterapie, UK, Praha  
Mgr. Hana Štorkánová | MUDr. Sabina Oreská | doc. MUDr. Michal Tomčík, Ph.D.  
Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 4 **Klinické zkušenosti s inhibitory Janus kináz**  
MUDr. Heřman Mann Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha
- 5 **Injekční roztok v předplněném injekčním peru – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 5 **Co je nového v oblasti biosimilárních léků – diskuze pokračuje**  
MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha
- 6 **Dexketoprofen v léčbě bolesti**  
MUDr. Marek Hák, Ph.D. Centrum léčby bolesti, Medicinicare, s. r. o., Chirurgická klinika FN a LF MU, Brno
- 6 **Tofacitinib: nové poznatky o jeho účinnosti v léčbě revmatoidní artritidy**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 6 **Baricitinib a jeho možnosti v léčbě revmatoidní artritidy**  
MUDr. Zdeněk Fojtík, Ph.D. Revmatologická ambulance, Interní hematologická a onkologická klinika, FN Brno a LF MU, Brno
- 6 **Role inhibice IL-6 v léčbě revmatoidní artritidy**  
MUDr. Marie Sedláčková Revmatologické a rehabilitační oddělení, Thomayerova nemocnice, Praha

# Strukturu modifikující léčba u osteoartrózy. Mýtus, nebo realita?

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 **Bijlsma, J. W. J.**: Strategies for the prevention and management of osteoarthritis of the hip and knee. *Best Pract Res Clin Rheumatol*, 2007, 21, s. 59–76.
- 2 **Cross, M. – Smith, E. – Hoy, D., et al.**: The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis*, 2014, 73, s. 1323–1330.
- 3 **Bruyere, O. – Cooper, C. – Pelletier, J. P., et al.**: A consensus statement of ESCO algorithm for the management of knee OA – from evidence based medicine to real life setting. *Sem Arthritis Rheum*, 2016, 45, s. 53–11.
- 4 **Pelletier, J. P. – Raynaud, J. P. – Beaulieu, A. D., et al.**: Chondroitin sulfate efficacy versus celecoxib on knee OA structural changes using MRI imaging: a two-year multicentre exploratory study. *Arthritis Res Ther*, 2016, 18, s. 256.
- 5 **Huang, Z. – Ding, Ch. – Lid, T., et al.**: Current status and future prospects for disease modification in osteoarthritis. *Rheumatology*, 2018, 57, s. iv108–iv123.
- 6 **Pavelka, K. – Gatterová, J. – Olejárová, M., et al.**: Glucosamine sulphate use and delay of progression of knee osteoarthritis. *Arch Intern Med*, 2002, 126, s. 2113–123.
- 7 **Reginster, J. Y. – Derouisy, R. – Rovati, L. C., et al.**: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. *Lancet*, 2001, 357, s. 251–256.
- 8 **Michel, B. A. – Stucki, G. – Frey, D., et al.**: Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. *Arthritis Rheum*, 2005, 52, s. 779–786.
- 9 **Kahan, A. – Uebelhart, D. – De Vathaire, F., et al.**: Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol*, 2009, 60, s. 524–533.
- 10 **Fransen, M. – Agalio, M. – Naim, L., et al.**: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. *Ann Rheum Dis*, 2015, 74, s. 851–858.
- 11 **Douglas, M. – Nguyen, M. – Berdahl, L., et al.**: Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODI-AH, a three-year, placebo controlled trial. *Arthritis Rheum*, 2001, 44, s. 2539–2547.
- 12 **Jubb, R. W. – Piva, S. – Beinat, L., et al.**: A one-year, randomised, placebo (saline) controlled clinical trials of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. *Int J Clin Pract*, 2003, 57, s. 467–474.
- 13 **Altman, R. – Lim, S. – Steen, G. – Dsa, V.**: Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: Evidence from a Large U.S. Health Claims Database. *PLoS ONE*, 2015, 10, e0145776, doi: 10.1371/journal.pone.0145776.
- 14 **Maheu, E. – Cadet, C. – Marty, M., et al.**: Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. *Ann Rheum Dis*, 2014, 73, s. 376–384, doi: 10.1136/annrheumdis-2012-202485.
- 15 **Brandt, K. D. – Mazzuca, S. A. – Katz, B. P., et al.**: Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. *Arthritis Rheum*, 2005, 52, s. 2015–2025.
- 16 **Reginster, J. Y. – Badurski, J. – Bellamy, N., et al.**: Extended report: efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. *Ann Rheum Dis*, 2013, 72, e13.
- 17 **Bingham, C. O. 3<sup>rd</sup> – Buckland-Wright, J.C. – Gernaro, P., et al.**: Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. *Arthritis Rheum*, 2006, 54, s. 3494–3507.
- 18 **Laslett, L. L. – Kingsbury, S. R. – Hensor, E. M., et al.**: Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. *Ann Rheum Dis*, 2014, 73, s. 824–830.
- 19 **Fu, S. H. – Wang, C. Y., et al.**: Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis. *J Bone Joint Surg Am*, 2017, 99, s. 938–946.
- 20 **Dahlberg, L. E. – Aydemir, A. – Muurhainen, N., et al.**: A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis. *Clin Exp Rheumatol*, 2016, 34, s. 445–450.
- 21 **Vega, A. – Martin-Ferrero, M. A. – Del, C. F., et al.**: Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized, controlled trial. *Transplantation*, 2015, 99, s. 1681–1690.
- 22 **Yves-Maria, P. – Lars, P. – Rosanna, F., et al.**: Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. *Stem Cells Transl Med*, 2016, 5, s. 847.
- 23 **Raynaud, J. P. – Martel, P. J. P.**: Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. *Ann Rheum Dis*, 2009, 68, s. 938–947.

## Osteoporóza u mužů

prof. MUDr. Jan Štěpán, DrSc. Revmatologický ústav a 1. LF UK, Praha

- 1 **Svedbom, A. – Hernlund, E. – Ivergård, M., et al.**: Osteoporosis in the European Union: a compendium of country-specific reports. *Arch Osteoporos*, 2013, 8, s. 35–42.
- 2 **Bliuc, D. – Nguyen, N. D. – Milch, V. E., et al.**: Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. *JAMA*, 2009, 301, s. 513–521.
- 3 **Rosa, J. – Šenk, F. – Palička, V.**: Diagnostika a léčba postmenopauzální osteoporózy. Stanovisko Společnosti pro metabolická onemocnění skeletu ČLS JEP 2015. *Osteologický Bull*, 2015, 20, s. 150–168.
- 4 **Kanis, J. A. – McCloskey, E. V. – Johansson, H., et al.**: A reference standard for the description of osteoporosis. *Bone*, 2008, 42, s. 467–475.
- 5 **Kanis, J. A. – McCloskey, E. V. – Johansson, H., et al.**: Development and use of FRAX in osteoporosis. *Osteoporos Int*, 2010, 21, suppl. 2, s. S407–S413.
- 6 **Kanis, J. A.**: Group obot WHOS: *Assessment of osteoporosis at the primary health care level. Report of a WHO Study Group*. Sheffield, University of Sheffield Medical School, UK, 2007.
- 7 **Leslie, W. D. – Lix, L. M.**: Comparison between various fracture risk assessment tools. *Osteoporos Int*, 2014, 25, s. 1–21.
- 8 **Ettinger, B. – Ensrud, K. E. – Blackwell, T., et al.**: Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. *Osteoporos Int*, 2013, 24, s. 1185–1193.
- 9 **Trajanoska, K. – Schoufour, J. D. – Darweesh, S. K., et al.**: Sarcopenia and its clinical correlates in the general population: The Rotterdam Study. *J Bone Miner Res*, 2018, 33, s. 1209–1218.
- 10 **Farr, J. N. – Xu, M. – Weivoda, M. M., et al.**: Targeting cellular senescence prevents age-related bone loss in mice. *Nat Med*, 2017, 23, s. 1072–1079.
- 11 **Ho-Pham, L. T. – Nguyen, U. D. – Nguyen, T. V.**: Association between lean mass, fat mass, and bone mineral density: a meta-analysis. *J Clin Endocrinol Metab*, 2014, 99, s. 30–38.
- 12 **Khosla, S. – Monroe, D. G.**: Regulation of bone metabolism by sex steroids. *Cold Spring Harb Perspect Med*, 2018, 8.
- 13 **Ferrari, S. L. – Deutsch, S. – Baudoin, C., et al.**: LRP5 gene polymorphisms and idiopathic osteoporosis in men. *Bone*, 2005, 37, s. 770–775.
- 14 **Kanis, J. A. – Bianchi, G. – Bilezikian, J. P., et al.**: Towards a diagnostic and therapeutic consensus in male osteoporosis. *Osteoporos Int*, 2011, 22, s. 2789–2798.
- 15 **Mellstrom, D. – Vandenput, L. – Mallmin, H., et al.**: Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. *J Bone Miner Res*, 2008, 23, s. 1552–1560.
- 16 **Amory, J. K. – Watts, N. B. – Easley, K. A., et al.**: Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. *J Clin Endocrinol Metab*, 2004, 89, s. 503–510.
- 17 **Orwoll, E. – Ettinger, M. – Weiss, S., et al.**: Alendronate for the treatment of osteoporosis in men. *N Engl J Med*, 2000, 343, s. 604–610.
- 18 **Boonen, S. – Orwoll, E. S. – Wenderoth, D., et al.**: Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. *J Bone Miner Res*, 2009, 24, s. 719–725.
- 19 **Orwoll, E. S. – Binkley, N. C. – Lewiecki, E. M., et al.**: Efficacy and safety of monthly ibandronate in men with low bone density. *Bone*, 2010, 46, s. 970–976.
- 20 **Boonen, S. – Reginster, J. Y. – Kaufman, J. M., et al.**: Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med*, 2012, 367, s. 1714–1723.
- 21 **Langdahl, B. L. – Teglbjaerg, C. S. – Ho, P. R., et al.**: A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. *J Clin Endocrinol Metab*, 2015, 100, s. 1335–1342.
- 22 **Smith, M. R. – Egerdie, B. – Hernández Toriz, N., et al.**: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med*, 2009, 361, s. 745–755.
- 23 **Chang, J. – Hakam, A. E. – McCauley, L. K.**: Current understanding of the pathophysiology of osteonecrosis of the jaw. *Curr Osteoporos Rep*, 2018, 16, s. 584–595.
- 24 **Adler, R. A. – El-Hajj Fuleihan, G. – Bauer, D. C., et al.**: Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res*, 2016, 31, s. 16–35.
- 25 **Orwoll, E. S. – Scheele, W. H. – Paul, S., et al.**: The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. *J Bone Miner Res*, 2003, 18, s. 9–17.
- 26 **Gluer, C. C. – Marin, F. – Ringe, J. D., et al.**: Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. *J Bone Miner Res*, 2013, 28, s. 1355–1368.
- 27 **Chen, L. X. – Zhou, Z. R. – Li, Y. L., et al.**: Comparison of bone mineral density in lumbar spine and fracture rate among eight drugs in treatments of osteoporosis in men: a network meta-analysis. *PLoS One*, 2015, 10, s. e0128032.
- 28 **Mikyas, Y. – Agodoa, I. – Yurgin, N.**: A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men. *Applied health economics and health policy*, 2014, 12, s. 267–277.
- 29 **Geffken, D. F. – Cushman, M. – Burke, G. L., et al.**: Association between physical activity and markers of inflammation in a healthy elderly population. *Am J Epidemiol*, 2001, 153, s. 242–250.
- 30 **Byberg, L. – Bellavia, A. – Larsson, S. C., et al.**: Mediterranean diet and hip fracture in swedish men and women. *J Bone Miner Res*, 2016, 31, s. 2098–2105.

## Inhibitory tumor nekrotizujícího faktoru alfa nebo inhibitory interleukinu 17 v terapii pacientů s axiální spondyloartritidou?

MUDr. Monika Gregová, Ph.D. Revmatologický ústav, Klinika revmatologie 1. LF UK, Praha

- 1 **Sieper, J. – Rudwaleit, M. – Baraliakos, X., et al.**: The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis*, 2009, 68, suppl. 2, ii.1.
- 2 **Rudwaleit, M. – van der Heijde, D. – Landewé, R., et al.**: The development of Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis*, 2011, 70, s. 25–31.
- 3 **Qu, N. – Xu, M. – Mizoguchi, I., et al.**: Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. *Clin Dev Immunol*, 2013, 2013, s. 1–13.
- 4 **Sherlock, J. P. – Buckley, C. D. – Cua, J. D., et al.**: The critical role of interleukin-23 in spondyloarthritis. *Mol Immunol*, 2014, 57, s. 38–43.
- 5 **Appel, H. – Maier, R. – Wu, P., et al.**: Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests the innate immune

- pathway might be of greater relevance than the Th17-mediated adaptive immune response. *Arthritis Res Ther*, 2011, 13, s. R95.
- 7 Appel, H. – Maier, R. – Bleil, J., et al.: In situ analysis of IL-23 secreting cells in the spine of patients with ankylosing spondylitis. *Arthritis Rheum*, 2013, 65, s. 1522–1529.
  - 8 van der Heijde, D. – Ramiro, S. – Landewé, R., et al.: 2016 update of the ASAS-EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*, 2017, 76, s. 978–991.
  - 9 van der Heijde, D. – Deodhar, A. – Wei, J. C., et al.: Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. *Ann Rheum Dis*, 2017, 76, s. 1340.
  - 10 Patel, D. D. – Kuchroo, V. K.: Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. *Immunity*, 2015, 43, s. 1040–1051.
  - 11 Ward, M. M. – Deodhar, A. – Akl, E. A., et al.: American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Care Res*, 2016, 68, s. 151–166.
  - 12 Machado, M. A. – Barbosa, M. M. – Almeida, A. M., et al.: Treatment on ankylosing spondylitis with TNF blockers: a meta-analysis. *Rheumatol Int*, 2013, 33, s. 2199–2213.
  - 13 Callhoff, J. – Sieper, J. – Weiss, A., et al.: Efficacy of TNF- $\alpha$  blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. *Ann Rheum Dis*, 2015, 74, s. 1241–1248.
  - 14 Maxwell, L. J. – Zochling, J. – Boonen, A., et al.: TNF- $\alpha$  inhibitors for ankylosing spondylitis. *Cochrane Database Syst Rev*, 2015, CD005468.
  - 15 van der Heijde, D. – Kivitz, A. – Schiff, M. H., et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2006, 54, s. 2136–2146.
  - 16 van der Heijde, D. – Dijkman, B. – Geusens, P., et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSET). *Arthritis Rheum*, 2005, 52, s. 582–591.
  - 17 Brandt, J. – Khariousov, A. – Listing, J., et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis Rheum*, 2003, 48, s. 1667–1675.
  - 18 Beaten, D. – Sieper, J. – Braun, J., et al.: Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. *N Engl J Med*, 2015, 373, s. 2534–2548.
  - 19 Pavelka, K. – Kivitz, A. – Dokoupilova, E., et al.: Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. *Arthritis Res Ther*, 2017, 19, s. 285.
  - 20 Marzo-Ortega, H. – Sieper, J. – Kivitz, A., et al.: Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. *AMD Open*, 2017, 3, e000592.
  - 21 Deodhar, A. – Conaghan, P. G. – Kvien, T. K., et al.: Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. *Clin Exp Rheumatol*, 2018, 37, s. 260–269.
  - 22 Sieper, J. – Deodhar, A. – Marzo-Ortega, H., et al.: Secukinumab efficacy in anti-TNF-naïve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. *Ann Rheum Dis*, 2017, 76, s. 571–592.
  - 23 Sieper, J. – Poddubnyy, D.: New evidence on the management of spondyloarthritis. *Nat Rev Rheumatol*, 2016, 12, s. 282–295.
  - 24 Beaten, D. – Sieper, J. – Braun, J., et al.: Secukinumab, an IL-17A inhibitor, in ankylosing spondylitis. *N Engl J Med*, 2015, 373, s. 2534–2548.
  - 25 Kammüller, M. – Tsai, T-F. – Griffiths, C. E., et al.: Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infection. *Clin Transl Immunol*, 2017, 6, e152.
  - 26 Havrdová, E. – Belova, A. – Goloborodko, A., et al.: Activity of ecucinumab, an IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. *J Neurol*, 2016, 263, s. 1287–1295.
  - 27 Dougados, M. – van der Heijde, D. – Sieper, J., et al.: Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicentre randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2014, 66, s. 2091–2102.
  - 28 Maksymowych, W. P. – Salonen, D. – Inman, R. D., et al.: Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. *J Rheumatol*, 2010, 37, s. 1728–1734.
  - 29 Lambert, R. G. – Salonen, D. – Rahman, P., et al.: Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicentre, randomized, double-blind, placebo-controlled study. *Arthritis Rheum*, 2007, 56, s. 4005–4014.
  - 30 Song, I. H. – Hermann, K. G. – Haibel, H., et al.: Prevention of new osteitis in magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. *Rheumatology (Oxford)*, 2015, 54, s. 257–261.
  - 31 van der Heijde, D. – Baraliakos, X. – Hermann, K. A., et al.: Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. *Ann Rheum Dis*, 2018, 77, s. 699–705.
  - 32 Haroon, N. – Inman, R. D. – Leach, T. J., et al.: The impact of tumor necrosis factor  $\alpha$  inhibitors on radiographic progression in ankylosing spondylitis. *Arthritis Rheumatol*, 2013, 65, s. 2645–2654.
  - 33 Braun, J. – Baraliakos, X. – Deodhar, A., et al.: Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. *Rheumatology (Oxford)*, 2018, doi: 10.1093/rheumatology/key375, Epub před tiskem.
  - 34 Baraliakos, X. – Braun, J. – Deodhar, A., et al.: Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Kongres EULAR, 13.–16. 6. 2018, Amsterdam, Nizozemsko, poster SAT 0268.
  - 35 de Winter, J. J. – van Mens, L. J. – van der Heijde, D., et al.: Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. *Arthritis Res Ther*, 2016, 18, s. 196.
  - 36 Pérez Alamino, R. – Maldonado Cocco, J. A. – Citera, G., et al.: Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease. *J Rheumatol*, 2011, 38, s. 1656.
  - 37 Nash, P. – Lubrano, E. – Cauli, A., et al.: Updated guidelines for the management of axial disease in psoriatic arthritis. *J Rheumatol*, 2014, 41, s. 2286–2289.
  - 38 Langley, R. G. – Elewski, B. E. – Leibold, M., et al.: Secukinumab in plaque psoriasis – results of two phase 3 trials. *N Engl J Med*, 2014, 371, s. 326–338.
  - 39 Mease, P. – van der Heijde, D. – Landewé, R., et al.: Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis*, 2018, 77, s. 890–897.
  - 40 Griffiths, C. E. M. – Reich, K. – Lebwohl, M., et al.: Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*, 2015, 386, s. 541–551.
  - 41 Stolwijk, C. – van Tubergen, A. – Castillo-Ortiz, J. D., et al.: Prevalence of extraarticular manifestation in patients with ankylosing spondylitis: a systemic review and meta-analysis. *Ann Rheum Dis*, 2015, 74, s. 65.
  - 42 Jabs, D. A. – Nussenblatt, R. B. – Rosenbaum, J. T.: Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol*, 2005, 140, s. 509.
  - 43 Oliveira, T. L. – Maksymowych, W. P. – Lambert, R. G. W., et al.: Sacroiliac joint magnetic resonance imaging in asymptomatic patients with recurrent acute anterior uveitis: a proof-of-concept study. *J Rheumatol*, 2017, 44, s. 1833–1840.
  - 44 Jaffe, G. J. – Dick, A. D. – Brézin, A. P., et al.: Adalimumab in patients with active non-infectious uveitis. *N Engl J Med*, 2016, 375, s. 932.
  - 45 Nguyen, Q. D. – Merrill, P. T. – Jaffe, G. J., et al.: Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 1183.
  - 46 Wu, D. – Guo, Y. Y. – Xu, N. N., et al.: Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. *BMC Musculoskelet Disord*, 2015, 16, s. 19.
  - 47 Galor, A. – Perez, V. L. – Hammel, J. P., et al.: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. *Ophthalmology*, 2006, 113, s. 2371.
  - 48 Foeldvari, I. – Nielsen, S. – Kümmerle-Deschner, J., et al.: Tumor necrosis factor- $\alpha$  blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. *J Rheumatol*, 2007, 34, s. 1146.
  - 49 Dick, A. D. – Tugal-Tutkun, I. – Foster, S., et al.: Secukinumab in the treatment of non-infectious uveitis: results of three randomized, controlled clinical trials. *Ophthalmology*, 2013, 120, s. 777–787.
  - 50 Letko, E. – Yeh, S. – Foster, C. S., et al.: Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. *Ophthalmology*, 2015, 122, s. 939.
  - 51 Rudwaleit, M. – Beaten, D.: Ankylosing spondylitis and bowel disease. *Best Pract Res Clin Rheumatol*, 2006, 20, s. 451–471.
  - 52 Lee, J. S. – Tato, C. M. – Joyce-Shaikh, B., et al.: Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. *Immunity*, 2015, 43, s. 727–738.
  - 53 Hueber, W. – Sands, B. E. – Lewitzky, S., et al.: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut*, 2012, 61, s. 1693–1700.
  - 54 Schreiber, S. – Colombel, J-F. – Feagan, B. G., et al.: Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. *Ann Rheum Dis*, 2019, 78, s. 473–479.
  - 55 Schett, G. – Elewaut, D. – McInnes, I. B., et al.: Toward a cytokine-based disease taxonomy. *Nature Med*, 2013, 7, s. 822–825.

## Léčba polymorbidního pacienta s revmatoidní artritidou v kazuistikách a možnosti uplatnění nového inhibitoru IL-6

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Smolen, J. S. – Laddewé, R. – Bijlsma, J., et al.: EULAR Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- 2 Šenolt, L. – Mann, H. – Závada, J. – Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. *Česká revmatologie*, 2017, 1, s. 8–24.
- 3 Smolen, J. S. – Aletaha, D. – McInnes, I. B.: Rheumatoid arthritis. *Lancet*, 2016, 388, s. 2763–2774.
- 4 van den Hoek, J. – Boshuizen, H. C. – Roorda, L. D., et al.: Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. *Rheumatology Int*, 2017, 37, s. 487–493.
- 5 Dougados, M. – Soubrier, M. – Antunez, A., et al.: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). *Ann Rheum Dis*, 2014, 73, s. 62–68.
- 6 McInnes, I. B. – Schett, G.: Pathogenetic insights from the treatment of rheumatoid arthritis. *Lancet*, 2017, 389, s. 2328–2337.
- 7 Ho, L. J. – Luo, S. F. – Lai, J. H.: Biological effects of interleukin-6: clinical applications in autoimmune disease and cancers. *Biochem Pharmacol*, 2015, 97, s. 16–26.
- 8 Genovese, M. C. – Fleischmann, R. – Kivitz, A. J., et al.: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate. *Arthritis Rheum*, 2015, 67, s. 1424–1437.
- 9 Fleischmann, R. – van Adelsbert, J. – Lin, Y., et al.: Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheum*, 2017, 69, s. 277–290.
- 10 Burmester, G. R. – Lin, Y. – Patel, R., et al.: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*, 2017, 76, s. 840–847.
- 11 Strand, V. – Kosinski, M. – Chen, C. I., et al.: Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. *Arthritis Res Ther*, 2016, 18, s. 198.
- 12 Gottenberg, J. E. – Brocq, O. – Perdriger, A., et al.: Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. *JAMA*, 2016, 316, s. 1172–1180.
- 13 Smolen, J. S. – van der Heijde, D. – Machold, K. P., et al.: Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2014, 73, s. 3–5.
- 14 Smolen, J. S. – Aletaha, D. – Bijlsma, J. W., et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis*, 2010, 69, s. 631–637.
- 15 Aletaha, D. – Alasti, F. – Smolen, J. S., et al.: Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. *Ann Rheum Dis*, 2016, 75, s. 1479–1485.

# Pokroky v léčbě plicní arteriální hypertenze u systémových onemocnění pojiva

doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav a revmatologická klinika 1. LF UK, Praha

- Hoepfer, M. M. – Bogaard, H. J. – Condliffe, R., et al.: Definition and diagnosis of pulmonary hypertension. *J Am Coll Cardiol*, 2013, 62, s. D42–D50.
- Jansa, P. – Aschermann, M., et al.: Plicní arteriální hypertenze u systémových onemocnění pojiva. *Rheumatologia*, 2006, 20, s. 13–18.
- Mukerjee, D. – St George, D. – Coleiro, B., et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. *Ann Rheum Dis*, 2003, 62, s. 1088–1093.
- D'Alonzo, G. E. – Barst, R. J. – Ayres, S. M., et al.: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. *Ann Intern Med*, 1991, 115, s. 343–349.
- Jansa, P.: Léčba plicní arteriální hypertenze. *Remedia*, 2014, 24, s. 260–263.
- Galiè, N. – Humbert, M. – Vachiery, J. L., et al.: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*, 2016, 37, s. 67–119.
- McGoan, M. – Gutterman, D. – Steen, V., et al.: Screening, early detection, and diagnosis of pulmonary arterial hypertension. *Chest*, 2004, 126, s. 145–149.
- Galiè, N. – Corris, P. A. – Frost, A., et al.: Updated treatment algorithm of pulmonary arterial hypertension. *J Am Coll Cardiol*, 2013, 62, s. D60–D72.
- Sitbon, O. – Delcroix, M. – Bergot, E., et al.: EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. *Am Heart J*, 2014, 167, s. 210–217.
- Badesch, D. B. – Tapson, V. F. – McGoan, M. D., et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med*, 2000, 132, s. 425–434.
- Olschewski, H. – Simonneau, G. – Galiè, N., et al.: Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*, 2002, 347, s. 322–331.
- Barst, R. J. – McGoan, M. D. – McLaughlin, V. V., et al.: Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol*, 2003, 41, s. 2119–2125.
- Gainè, S. – Chin, K. – Coghlan, G., et al.: Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. *Eur Respir J*, 2017, 50, s. 1602493.
- Denton, C. P. – Humbert, M. – Rubin, L., et al.: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. *Ann Rheum Dis*, 2006, 65, s. 1336–1340.
- Galiè, N. – Olschewski, H. – Oudiz, R. J., et al.: Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation*, 2008, 117, s. 3010–3019.
- Pulido, T. – Adzerikho, I. – Channick, R. N., et al.: Macitentan and morbidity and mortality in pulmonary arterial hypertension. *N Engl J Med*, 2013, 369, s. 809–818.
- Galiè, N. – Ghofrani, H. A. – Torbicki, A., et al.: Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*, 2005, 353, s. 2148–2157.
- Galiè, N. – Denton, C. P. – Dardi, F., et al.: Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. *Int J Cardiol*, 2017, 235, s. 67–72.
- Humbert, M. – Coghlan, J. G. – Ghofrani, H. A., et al.: Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. *Ann Rheum Dis*, 2017, 76, s. 422–426.
- Coghlan, J. G. – Galiè, N. – Barbera, J. A., et al.: Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. *Ann Rheum Dis*, 2017, 76, s. 1219–1227.
- Hassoun, P. M. – Zamanian, R. T. – Damico, R., et al.: Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med*, 2015, 192, s. 1102–1110.
- McLaughlin, V. V. – Oudiz, R. J. – Frost, A., et al.: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*, 2006, 174, s. 1257–1263.
- Kowal-Bielecka, O. – Fransen, J. – Avouac, J., et al.: EUSTAR co-authors: Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis*, 2017, 76, s. 1327–1339.
- Hernández-Sánchez, J. – Harlow, L. – Church, C., et al.: Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. *Pulm Circ*, 2018, 8, 2045893217735820.
- Simonneau, G. – Hoepfer, M. M. – McLaughlin, V., et al.: Future perspectives in pulmonary arterial hypertension. *Eur Respir Rev*, 2016, 25, s. 381–389.

## Sexuální dysfunkce u pacientů s chronickým revmatickým onemocněním – problém, o kterém se příliš nemluví

Mgr. Barbora Heřmánková | Mgr. Maja Špiritović | Fakulta tělesné výchovy a sportu, Katedra fyzioterapie, UK, Praha

Mgr. Hana Štorkánová | MUDr. Sabina Oreská | doc. MUDr. Michal Tomčík, Ph.D.

Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- Almeida, P. H. – Castro Ferreira, C. – Kurizky, P. S., et al.: How the rheumatologist can guide the patient with rheumatoid arthritis on sexual function. *Revista Brasil Reumat*, 2015, 55, s. 458–463.
- Tristano, A. G.: The impact of rheumatic diseases on sexual function. *Rheumatol Int*, 2009, 29, s. 853–860.
- Impens, A. J. – Seibold, J. R.: Vascular alterations and sexual function in systemic sclerosis. *Int J Rheumatol*, 2010, s. 139020.
- Merayo-Chalico, J. – Barrera-Vargas, A. – Morales-Padilla, S., et al.: Epidemiologic profile of erectile dysfunction in patients with systemic lupus erythematosus: the Latin American landscape. *J Rheumatol*, 2019, 46, s. 397–404.
- Areskoug-Josefsson, K. – Öberg, U.: A literature review of the sexual health of women with rheumatoid arthritis. *Musculoskeletal Care*, 2009, 7, s. 219–226.
- Zhao, S. – Li, E. – Wang, J., et al.: Rheumatoid arthritis and risk of sexual dysfunction: a systematic review and metaanalysis. *J Rheumatol*, 2018, 45, s. 1375–1382.
- Dorner, T. E. – Berner, C. – Haider, S., et al.: Sexual health in patients with rheumatoid arthritis and the association between physical fitness and sexual function: a cross-sectional study. *Rheumatol Int*, 2018, 38, s. 1103–1114.
- Zhang, Q. – Zhou, C. – Chen, H., et al.: Rheumatoid arthritis is associated with negatively variable impacts on domains of female sexual function: evidence from a systematic review and meta-analysis. *Psychol Health Med*, 2018, 23, s. 114–125.
- Hill, J. – Bird, H. – Thorpe, R.: Effects of rheumatoid arthritis on sexual activity and relationships. *Rheumatology*, 2003, 42, s. 280–286.
- Fan, D. – Liu, L. – Ding, N., et al.: Male sexual dysfunction and ankylosing spondylitis: a systematic review and metaanalysis. *J Rheumatol*, 2015, 42, s. 252–257.
- Bal, S. – Bal, K. – Turan, Y., et al.: Sexual functions in ankylosing spondylitis. *Rheumatol Int*, 2011, 31, s. 889–894.
- Fan, D. – Liu, L. – Ding, N., et al.: Male sexual dysfunction and ankylosing spondylitis: a systematic review and metaanalysis. *J Rheumatol*, 2015, 42, s. 252–257.
- Sarıyıldız, M. – Batmaz, I. – Inanir, A., et al.: The impact of ankylosing spondylitis on female sexual functions. *Int J Impotence Res*, 2013, 25, s. 104.
- Yin, R. – Xu, B. – Li, L., et al.: The impact of systemic lupus erythematosus on women's sexual functioning: A systematic review and meta-analysis. *Medicine*, 2017, 96, s. e7162.
- Seawell, A. H. – Danoff-Burg, S.: Body image and sexuality in women with and without systemic lupus erythematosus. *Sex Roles*, 2005, 53, s. 865–876.
- Shen, B. – He, Y. – Chen, H., et al.: Body image disturbances have impact on the sexual problems in Chinese systemic lupus erythematosus patients. *J Immunol Res*, 2015.
- van Nimwegen, J. F. – Arends, S. – van Zuiden, G. S., et al.: The impact of primary Sjögren's syndrome on female sexual function. *Rheumatology*, 2015, 54, s. 1286–1293.
- Priori, R. – Minniti, A. – Derme, M., et al.: Quality of sexual life in women with primary Sjögren syndrome. *J Rheumatol*, 2015, 42, s. 1427–1431.
- Jaeger, V. K. – Walker, U. A.: Erectile dysfunction in systemic sclerosis. *Cur Rheum Reports*, 2016, 18, s. 49.
- Levis, B. – Hudson, M. – Knafo, R., et al.: Rates and correlates of sexual activity and impairment among women with systemic sclerosis. *Arthritis Care Res*, 2012, 64, s. 340–350.
- Saad, S. C. – Pietrzykowski, J. – Lewis, S. S., et al.: Vaginal lubrication in women with scleroderma and Sjogren's syndrome. *Sexuality and Disability*, 1999, 17, s. 103–113.
- Bhadauria, S. – Moser, D. K. – Clements, P. J., et al.: Genital tract abnormalities and female sexual function impairment in systemic sclerosis. *Am J Obstet Gynecol*, 1995, 172, s. 580–587.
- Proietti, M. – Aversa, A. – Letizia, C., et al.: Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. *J Rheumatol*, 2007, 34, s. 1712–1717.

## Klinické zkušenosti s inhibitory Janus kináz

MUDr. Heřman Mann Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha

- Shuai, K. – Liu, B.: Regulation of JAK-STAT signalling in the immune system. *Nat Rev Immunol*, 2003, 3, s. 900–911.
- Fleischmann, R. – Kremer, J. – Cush, J., et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 495–507.
- Kremer, J. – Li, Z. G. – Hall, S. – Fleischmann, R., et al.: Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med*, 2013, 159, s. 253–261.
- van der Heijde, D. – Tanaka, Y. – Fleischmann, R., et al.: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis Rheum*, 2013, 65, s. 559–570.
- van Vollenhoven, R. F. – Fleischmann, R. – Cohen, S., et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 508–519.
- Fleischmann, R. – Mysler, E. – Hall, S., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 390, s. 457–468.
- Lee, E. B. – Fleischmann, R. M. – Hall, S., et al.: Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naïve patients with rheumatoid arthritis [ACR abstract 2486]. *Arthritis Rheum*, 2012, 64, suppl., s. S1049.
- Burmester, G. R. – Blanco, R. – Charles-Schoeman, C., et al.: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet*, 2013, 381, s. 451–460.
- Dougados, M. – van der Heijde, D. – Chen, Y. C., et al.: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Ann Rheum Dis*,

- 2017, 76, s. 88–95.
- 10 **Genovese, M. C. – Kremer, J. – Zamani, O., et al.:** Baricitinib in patients with refractory rheumatoid arthritis. *N Engl J Med*, 2016, 374, s. 1243–1252.
  - 11 **Fleischmann, R. – Schiff, M. – van der Heijde, D., et al.:** Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. *Arthritis Rheumatol*, 2017, 69, s. 506–517.
  - 12 **Taylor, P. C. – Keystone, E. C. – van der Heijde, D., et al.:** Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*, 2017, 376, s. 652–662.
  - 13 **Šenolt, L. – Mann, H. – Závada J., et al.:** Doporučení České reumatologické společnosti pro farmakoterapii revmatoidní artritidy. *Česká Reumatologie*, 2017, 25, s. 8–24.
  - 14 **Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.:** EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
  - 15 **Winthrop, K. L.:** The emerging safety profile of JAK inhibitors in rheumatic disease. *Nat Rev Rheumatol*, 2017, 13, s. 234–243.
  - 16 **Kremer, J. – Cappelli, L. C. – Etzel, C. J., et al.:** A real-world data from a post-approval safety surveillance study of tofacitinib vs biologic dmards and conventional synthetic dmards: five-year results from a US-based rheumatoid arthritis registry [abstract]. *Arthritis Rheumatol*, 2018, 70, suppl. 10, vyhledáno 19. 2. 2019.
  - 17 **Curtis, J. R. – Xie, F. – Yang, S., et al.:** Herpes zoster in tofacitinib: risk is further increased with glucocorticoids but not methotrexate. *Arthritis Care Res (Hoboken)*, 8. 10. 2018, Epub před tiskem.
  - 18 **Desai, R. J. – Pawar, A. – Weinblatt, M. E., et al.:** Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients. *Arthritis Rheumatol*, 15. 12. 2018, Epub před tiskem.
  - 19 **Mócsai, A. – Kovács, L. – Gergely, P.:** What is the future of targeted therapy in rheumatology: biologics or small molecules? *BMC Med*, 2014, 12, 43, doi:10.1186/1741-7015-12-43.

## Injekční roztok v předplněném injekčním peru – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 **Keininger, D. – Coteur, G.:** Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). *Health Qual. Life Outcomes*, 2011, 9, s. 2.
- 2 **Berteau, C. – Schwarzenbach, F. – Donazzolo, Y., et al.:** Evaluation of compliance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. *Patient Prefer Adherence*, 2010, 4, s. 379–388.
- 3 **Lugaresi, A. – Durastanti, V. – Gasperini, C., et al.:** Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by ReBject autoinjection over a 1-year period: the CoSa study. *Clin Neuropharmacol*, 2008, 31, s. 167–172.
- 4 **Cipriani, P. – Ruscitti, P. – Carubbi, F., et al.:** Methotrexate: an old new drug in autoimmune disease. *Expert Rev Clin Immunol*, 2014, 10, s. 1519–1530.
- 5 **Cipriani, P. – Ruscitti, P. – Carubbi, F., et al.:** Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. *Clin Ther*, 2014, 36, s. 427–435.
- 6 **Hudry, C. – Lebrun, A. – Moura, B., et al.:** Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. *Rheumatol Ther*, 2017, 4, s. 183–194.

## Co je nového v oblasti biosimilárních léků – diskuze pokračuje

MUDr. Mária Filková, Ph.D. Reumatologický ústav, Praha

- 1 **Smolen, J. S. – Landewe, R. – Bijlsma, J., et al.:** EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- 2 **Baumgart, D. C. – Misery, L. – Naeyaert, S., et al.:** Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? *Front Pharmacol*, 2019, 10, s. 279.
- 3 **Aletaha, D. – Smolen, J. S.:** Diagnosis and management of rheumatoid arthritis: a review. *JAMA*, 2018, 320, s. 1360–1372.
- 4 **Odinot, J. S. – Day, C. E. – Cruz, J. L., et al.:** The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. *J Manag Care Spec Pharm*, 2018, 24, s. 952–959.
- 5 **Smolen, J. S. – van der Heijde, D. – Machold, K. P., et al.:** Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2014, 73, s. 3–5.
- 6 **Kay, J. – Schoels, M. M. – Dorner, T., et al.:** Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. *Ann Rheum Dis*, 2018, 77, s. 165–174.
- 7 **Rutherford, A. I. – Galloway, J. B.:** Biosimilars in rheumatology: out of the laboratory and into practice. *Expert Rev Clin Immunol*, 2016, 12, s. 697–699.
- 8 **Kay, J. – Smolen, J. S.:** Biosimilars to treat inflammatory arthritis: the challenge of proving identity. *Ann Rheum Dis*, 2013, 72, s. 1589–1593.
- 9 **Kay, J.:** A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. *J Intern Med*, 2019.
- 10 **Yoo, D. H. – Hrycaj, P. – Miranda, P., et al.:** A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis*, 2013, 72, s. 1613–1620.
- 11 **Yoo, D. H. – Racewicz, A. – Brzeziński, J., et al.:** A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. *Arthritis Res Ther*, 2016, 18, s. 82.
- 12 **Yoo, D. H. – Prodanovic, N. – Jaworski, J., et al.:** Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. *Ann Rheum Dis*, 2017, 76, s. 355–363.
- 13 **Choe, J. Y. – Prodanovic, N. – Niebrzydowski, J., et al.:** A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*, 2017, 76, s. 58–64.
- 14 **Smolen, J. S. – Choe, J. Y. – Prodanovic, N., et al.:** Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. *Rheumatology*, 2017, 56, s. 1771–1779.
- 15 **Smolen, J. S. – Choe, J. Y. – Prodanovic, N., et al.:** Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. *Ann Rheum Dis*, 2018, 77, s. 234–240.
- 16 **Cohen, S. B. – Alten, R. – Kameda, H., et al.:** A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. *Arthritis Res Ther*, 2018, 20, s. 155.
- 17 **Alten, R. – Batko, B. – Hala, T., et al.:** Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. *RMD Open*, 2019, 5, s. e000876.
- 18 **Emery, P. – Vencovsky, J. – Sylwestrzak, A., et al.:** A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*, 2017, 76, s. 51–57.
- 19 **Emery, P. – Vencovsky, J. – Sylwestrzak, A., et al.:** 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. *Rheumatology*, 2017, 56, s. 2093–2101.
- 20 **Matsuno, H. – Tomomitsu, M. – Hagino, A., et al.:** Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. *Ann Rheum Dis*, 2018, 77, s. 488–494.
- 21 **Park, M. C. – Matsuno, H. – Kim, J., et al.:** Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. *Arthritis Res Ther*, 2019, 21, s. 122.
- 22 **Cohen, S. – Genovese, M. C. – Choy, E., et al.:** Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. *Ann Rheum Dis*, 2017, 76, s. 1679–1687.
- 23 **Cohen, S. – Pablos, J. L. – Pavelka, K., et al.:** An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. *Arthritis Res Ther*, 2019, 21, s. 84.
- 24 **Weinblatt, M. E. – Baranaukaite, A. – Niebrzydowski, J., et al.:** Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. *Arthritis & Rheumatology*, 2018, 70, s. 40–48.
- 25 **Weinblatt, M. E. – Baranaukaite, A. – Dokoupilova, E., et al.:** Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. *Arthritis & Rheumatology*, 2018, 70, s. 832–840.
- 26 **Cohen, S. B. – Alonso-Ruiz, A. – Klimiuk, P. A., et al.:** Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. *Ann Rheum Dis*, 2018, 77, s. 914–921.
- 27 **Cohen, S. B. – Burgos-Vargas, R. – Emery, P., et al.:** Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis. *Arthritis Care Res*, 2018, 70, s. 1598–1606.
- 28 **Yoo, D. H. – Suh, C. H. – Shim, S. C., et al.:** Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial. *BioDrugs Clin Immun Biopharm Gene Ther*, 2017, 31, s. 357–367.
- 29 **Park, W. – Suh, C. H. – Shim, S. C., et al.:** Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. *BioDrugs Clin Immun Biopharm Gene Ther*, 2017, 31, s. 369–377.
- 30 **Suh, C. H. – Yoo, D. H. – Berrocal Kasay, A., et al.:** Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. *J Intern Med*, 2019, 285, s. 653–669.
- 31 **Jorgensen, K. K. – Olsen, I. C. – Goll, G. L., et al.:** Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. *Lancet*, 2017, 389, s. 2304–2316.
- 32 **Goll, G. L. – Jorgensen, K. K. – Sexton, J., et al.:** Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. *J Intern Med*, 2019, 285, s. 653–669.
- 33 **Glintborg, B. – Sørensen, I. J. – Loft, A. G., et al.:** A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. *Ann Rheum Dis*, 2017, 76, s. 1426–1431.
- 34 **Scherlinger, M. – Germain, V. – Labadie, C., et al.:** Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. *Joint, bone, spine: revue du rhumatisme*, 2018, 85, s. 561–567.
- 35 **Germain, V. – Scherlinger, M. – Barnette, T., et al.:** Federation Hospitalo Universitaire A. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. *Ann Rheum Dis*, 2018, doi: 10.1136/annrheumdis-2018-214374.
- 36 **Glintborg, B. – Loft, A. G. – Omerovic, E., et al.:** To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. *Ann Rheum Dis*, 2019, 78, s. 192–200.
- 37 **Tweehuisen, L. – Huiskes, V. J. B. – van den Bemt, B. J. F., et al.:** Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. *Arthritis & Rheumatology*, 2018, 70, s. 1408–1418.
- 38 **Cantini, F. – Benucci, M.:** Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? *Ann Rheum Dis*, 2019, 78, s. e23.
- 39 **Cantini, F. – Benucci, M.:** Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching. *Ann Rheum Dis*, 2018, doi: 10.1136/annrheumdis-2018-214757.
- 40 **Tweehuisen, L. – van den Bemt, B. J. F. – van Ingen, I. L., et al.:** Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. *Arthritis & Rheumatology*, 2018, 70, s. 60–68.

## Dexketoprofen v léčbě bolesti

MUDr. Marek Hakl, Ph.D. Centrum léčby bolesti, Medicinicare, s. r. o., Chirurgická klinika FN a LF MU, Brno

- Hayball, P. J. – Nation, R. L. – Bochner, F.: Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. *Chirality*, 1992, 4, s. 484–487.
- Mauleon, D. – Artigas, R. – Garcia, M. L. – Carganico, G.: Preclinical and clinical development of dexketoprofen. *Drugs*, 1996, 52, suppl. 5, s. 24–45.
- Rudy, A. C. – Liu, Y. – Brater, C. – Hall, S. D.: Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers. *J Clin Pharmacol*, 1998, 38, s. 35–105.
- Mazario, J. – Roza, C. – Herrero, J. F.: The NSAID dexketoprofen trometamol is as potent as mu-opioids in the depression of wind-up and spinal cord nociceptive reflexes in normal rats. *Brain Res*, 1999, 816, s. 512–517.
- Carabaza, A. – Cabre, F. – Garcia, A. M., et al.: Stereoselective inhibition of rat brain cyclooxygenase by dexketoprofen. *Chirality*, 1997, 9, s. 281–285.
- Moreno, J. J. – Calvo, L. – Fernandez, F., et al.: Biological activity of ketoprofen and its optical isomers. *Eur J Pharmacol*, 1990, 183, s. 2263–2264.
- Ferrer, X. – Fernández, M. F. – Clavo, L., et al.: Anti-inflammatory activity of S(+)-ketoprofen in the carageenan-induced paw edema of the rat. *Methods Find Exp Clin Pharmacol*, 1994, 16, suppl. 1, s. 82.
- Barbanoj, M. J. – Antonijoan, R. M. – Gich, I.: Clinical pharmacokinetics of dexketoprofen. *Clin Pharmacokinet*, 2001, 40, s. 245–262.
- Jamali, F. – Brooks, D. R.: Clinical pharmacokinetics of ketoprofen and its enantiomers. *Clin Pharmacokin*, 1990, 19, s. 197–217.
- Gich, I. – Bayes, M. – Barbanoj, M. J., et al.: Bioinversion of R(-)-ketoprofen following oral administration in healthy volunteers. *Clin Drug Invest*, 1996, 11, s. 347–353.
- McGurk, M. – Robinson, P. – Rajayogeswaran, V., et al.: Clinical comparison of dexketoprofen trometamol, ketoprofen, and placebo in postoperative dental pain. *J Clin Pharmacol*, 1998, 38, s. 465–545.
- Bagan, J. V. – Lopez Arranz, J. S. – Valencia, E., et al.: Clinical comparison of dexketoprofen trometamol and dipyrone in postoperative dental pain. *J Clin Pharmacol*, 1998, 38, s. 555–645.
- Ezcurdia, M. – Cortejo, F. J. – Lanzon, R., et al.: Comparison of the efficacy and tolerability of dexketoprofen and ketoprofen in the treatment of primary dysmenorrhea. *J Clin Pharmacol*, 1998, 38, s. 655–735.
- Beltran, J. – Martin-Mola, E. – Figueroa, M., et al.: Comparison of dexketoprofen trometamol and ketoprofen in the treatment of osteoarthritis of the knee. *J Clin Pharmacol*, 1998, 38, s. 745–805.
- Doležal, T.: Dexketoprofen. *Remedia*, 2002, 12, s. 357–359.

## Tofacitinib: nové poznatky o jeho účinnosti v léčbě revmatoidní artritidy

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Taylor, P. C. – van de Laar, M. – Curtis, J. R., et al.: Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: a post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies. *Ann Rheum Dis*, 2019, 78, s. A1687.
- Kremer, J. – Bingham, C. – Cappelli, L., et al.: Post-approval comparative safety study of tofacitinib and biologic DMARDs: five-year results from a US-based rheumatoid arthritis registry. *Ann Rheum Dis*, 2019, 78, s. A82.

## Baricitinib a jeho možnosti v léčbě revmatoidní artritidy

MUDr. Zdeněk Fojtík, Ph.D. Revmatologická ambulance, Interní hematologická a onkologická klinika, FN Brno a LF MU, Brno

- Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- Meyer, D. M. – Jossion, M. I. – Li, X., et al.: Antiinflammatory activity and neutrophil reduction mediated by the JAK1/JAK3 inhibitor, CP-690,550 in rat adjuvant-induced arthritis. *J Inflamm*, 2010, 7, s. 41.
- Ghoreschi, K. – Jesson, M. I. – Li, X., et al.: Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). *J Immunol*, 2011, 186, s. 4234–4243.
- Fleischmann, R. – Schiff, M. – van der Heijde, D., et al.: Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. *Arthritis Rheumat*, 2017, 69, s. 506–517.
- Taylor, P. C. – Keystone, E. C. – van der Heijde, D., et al.: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*, 2017, 376, s. 652–662.
- Dougados, M. – van der Heijde, D. – Chen, Y., et al.: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Ann Rheum Dis*, 2017, 76, s. 88–95.
- Genovese, M. C. – Kremer, J. – Zamani, O., et al.: Baricitinib in patients with refractory rheumatoid arthritis. *M Engl J Med*, 2016, 374, s. 1243–1252.
- Smolen, J. S. – Genovese, M. C. – Takeuchi, T., et al.: Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. *J Rheumatol*, 2019, 46, s. 7–18.
- Smolen, J. S. – Li, Z. – Klar, R., et al.: Durability and maintenance of efficacy following prolonged treatment with baricitinib. Prezentováno na European League Against Rheumatism (EULAR), Madrid, Španělsko, 14.–17. 6. 2017a; FR10096.
- Takeuchi, T. – Genovese, M. – Haraoui, B., et al.: Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Prezentováno na European League Against Rheumatism (EULAR), Madrid, Španělsko, 14.–17. 6. 2017; poster SAT0072.
- Van der Heijde, D. – Schiff, M. – Tanaka, Y., et al.: Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. *RMD Open*, 2019, 5, e000898.
- Murakami, K. – Kobayashi, Y. – Uehara, S., et al.: A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. *PLoS ONE*, 2017, 12, e0181126, <https://doi.org/10.1371/journal.pone.0181126>.
- Taylor, P. C. – Lee, Y. C. – Fleischmann, R., et al.: Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial. *J Clin Med*, 2019, 8, s. 831.
- Michaud, K. – Pope, J. E. – Emery, P., et al.: Relative impact of pain and fatigue on work productivity in patients with rheumatoid arthritis from the RA-BEAM baricitinib trial. *Rheumatol Ther*, 2019, 6, s. 409–419.
- Smolen, J. S., et al.: Safety profile of baricitinib in patients with active rheumatoid arthritis: an integrated analysis. The European League Against Rheumatism (EULAR); Londýn, Anglie; 8.–11. 6. 2016, poster THU0166.
- Genovese, M. C. – Smolen, J. S. – Takeuchi, T., et al.: Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. European League Against Rheumatism (EULAR); Madrid, Španělsko; 12.–15. 6. 2019, poster THU0078.
- Singh, J. A. – Saag, K. G. – Bridges, S. L. Jr., et al.: 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*, 2016, 68, s. 1–26.
- Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0219356&tab=prices>, vyhledáno 5. 9. 2019.

## Role inhibice IL-6 v léčbě revmatoidní artritidy

MUDr. Marie Sedláčková Revmatologické a rehabilitační oddělení, Thomayerova nemocnice, Praha

- Gonzalez, A. – Maradit Kremers, H. – Crowson, C. S., et al.: The widening mortality gap between rheumatoid arthritis patients and the general population. *Arthritis Rheum*, 2007, 56, s. 3583–3587.
- Choy, E.: Understanding the dynamics: pathway involved in the pathogenesis of rheumatoid arthritis. *Rheumatology (Oxford)*, 2012, 51, suppl. 5, s. 3–11.
- Dayar, J. M. – Choy, E.: Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. *Rheumatology (Oxford)*, 2010, 49, s. 15–24.
- Calabrese, L. H. – Rose-John, S.: IL-6 biology: implications for clinical targeting in rheumatic disease. *Nat Rev Rheumatol*, 2014, 10, s. 720–727.
- Fournier, M. – Chen, C. I. – Kuznik, A., et al.: Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient. *Clinicoecon Outcomes Res*, 2019, 11, s. 117–128.
- Fleischmann, R. – van Adelsberg, J. – Lin, Y., et al.: Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol*, 2017, 69, s. 277–290.
- Burmester, G. – Dörner, T. – Strand, V., et al.: The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis*, 2016, 75, s. 974–982.